Overview

* TG Therapeutics Q3 2025 revenue was $161.7 mln, driven by BRIUMVI sales

* Company raises 2025 global revenue target to $600 mln, BRIUMVI U.S. target to $585 mln

* Completed $100 mln share repurchase, authorized additional $100 mln program

Outlook

* TG Therapeutics ( TGTX ) raises 2025 global revenue target to $600 mln

* Company increases 2025 BRIUMVI U.S. net revenue target to $585 mln

* Company cites strong market demand for raising revenue guidance

Result Drivers

* BRIUMVI SALES GROWTH - BRIUMVI U.S. net revenue grew 84% year-over-year, driven by strong market demand

* INTERNATIONAL EXPANSION - BRIUMVI approved in multiple new markets, including EU and Australia

* PIPELINE ADVANCEMENT - Ongoing Phase 3 trials for subcutaneous ublituximab and simplified BRIUMVI dosing

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $161.7

Revenue mln

Q3 Net $390.89

Income mln

Q3 $29.36

Operatin mln

g Income

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)